Regenxbio RGNX HCR — Accounts Receivable Gross Current
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Regenxbio in its filing.
Tagged under the XBRL concept us-gaap:AccountsReceivableGrossCurrent.
The source filing: Regenxbio’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:15 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336725
As of June 30, 2026 and December 31, 2025, the Company had recorded total accounts receivable of $4.4 million and $24.1 million, respectively, from Novartis under the Novartis License, which consisted primarily of Zolgensma and Itvisma royalties receivable. Royalties receivable as of June 30, 2026 included $3.3 million expected to be paid to HCR in accordance with the 2020 Royalty Purchase Agreement discussed in Note 7. The Company recognizes royalty revenue from net sales of Zolgensma and Itvisma in the period in which the underlying products are sold by Novartis, which in certain cases may require the Company to estimate royalty revenue for periods of net sales which have not yet been reported to the Company. Estimated royalties are reconciled to actual amounts reported in subsequent periods, and any differences are recognized as an adjustment to royalty revenue in the period the royalties are reported.
Item 1. Financial Statements.
FAQ
- What is Regenxbio's HCR — accounts receivable gross current?
- Regenxbio (RGNX) reported HCR — accounts receivable gross current of $3.3M in Q2 2026.
- How has Regenxbio's HCR — accounts receivable gross current changed year-over-year?
- Regenxbio's HCR — accounts receivable gross current decreased by 76.6% year-over-year, from $14.1M to $3.3M.
- What is the long-term trend for Regenxbio's HCR — accounts receivable gross current?
- Over 4 years (2021 to 2025), Regenxbio's HCR — accounts receivable gross current has grown at a 6.3% compound annual growth rate (CAGR), from $49.6M to $63.4M.
- What does HCR — accounts receivable gross current mean?
- This metric represents the total outstanding balance of invoices owed to the company by customers for products or services provided within the HCR segment before any allowances for doubtful accounts. It serves as a key indicator of the segment's short-term liquidity and the effectiveness of its credit and collection policies. Monitoring this balance helps investors assess the speed at which the company converts its HCR-related sales into actual cash inflows.
Ask your AI about Regenxbio's hcr — accounts receivable gross current.
Connect your AI assistant and compare it to peers, right in your chat.
